



Healthcare bridges to nowhere?

Genentech, Nov. 7, 2005

“Preliminary Data from Phase III Trials Show Lucentis is the First Investigational Therapy to Demonstrate Clinical Benefit over Visudyne in a Head-to-Head Study of Patients With Wet AMD”



VisionCare, Inc., Nov. 22, 2005
The Implantable Miniature Telescope. A study in AJO showed the device effective in more than 90% of participants with wet AMD....

Health Tech Assessment in US


Pluralism vs. Fragmentation

- FDA
- CMS
- CDC
- VHA
- AHRQ (EPCs, DeCIDE)
- States: DERP, MED, Washington HB 2575
- Health plans: BCBS TEC
- Academic
- Manufacturers
- Private HTA companies


What NICE does

- How should the technology be used in the NHS?
 - Clinical excellence
 - Effective use of NHS resources
- Systematic review of the evidence on clinical outcomes
- Comparative effectiveness
- Cost-effectiveness

Cost Effectiveness



Cost Effectiveness



No Lessons From NICE on...

- HTA as a tool for pricing
- HTA integrated with insurance “choice”
- HTA technical methods

The Lessons of NICE

1. Comparative and cost-effectiveness together
2. A ship under two flags
3. Political insulation
4. Clarity, transparency, engagement
5. Political vision and courage

Howard says it, Blair agrees, and now even the DPP admits it...

YES, YOU CAN FIGHT BACK AGAINST BURGLARS

FULL STORY
PAGE 2

NHS in 3-year wait for wonder drug

BREAST CANCER PILL: THE DEADLY DELAY

BREAST cancer victims face an agonising three-year wait on the NHS for a drug hailed as the biggest treatment breakthrough for 30 years. Doctors say Arimidex could

By **Jenny Hope**
Medical Correspondent

save or prolong the lives of thousands of women.

It dramatically reduces the chances of the cancer spreading and cuts the risk of severe

side-effects. But a decision on approving the drug is not due until March 2007.

Between now and then, the disease will claim the lives of nearly 30,000 women.

At least 10,000 new patients a


Turn to Page 6, Col 4



Julia's baby girl
in intensive care

SEE PAGE SEVEN

Would NICE/USA harm patients?



Source: Gieringer, DH. *Cato Journal* 5, No. 1
(Spring/Summer 1985): 177-201

Would NICE/USA supplant your doctor?

“Assessing risks and costs, as well as benefits, has been central to the exercise of good medical judgment by individual physicians for decades. The advantage the individual physician has over any national center or advisory council is that he or she is dealing with individuals in need of medical care, not hypothetical cases.”

----AMA representative's Congressional testimony

Would NICE/USA kill innovation?

- Yes
- No

Bridges to nowhere?

- What do we do without a NICE?
 - Nothing
 - Decentralize
 - Empower the market
 - Centralize in the FDA
 - Centralize elsewhere in the fed government
 - Mixed public-private models of HTA